Boan’s BA2101 Administered for First Patient in Clinical Trial

Boan Biotech announced that BA2101, a self-developedinvestigational anti-IL-4Rα antibody , has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innova...

Boan’s BA1106 Administered for First Patient in Clinical Trial

Boan Biotech today announced that BA1106, aself developed investigational non-IL-2 blocking anti-CD25 antibody has been administered for the first patient in a Phase I clinical trial. This trial is de...

List of Directors and their Roles and Functions

Passing Away of a Non-Executive Director

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023

Stabilizing Actions, End of Stabilization Period and Lapse of the Over-Allotment Option

Boan Biotech Publishes Research Results of Self-Developed Neutralizing Antibody Against SARS-CoV-2 Variants in Nature Sub-Journal

Boan Biotech announces recently that the research paper Biparatopic Antibody BA7208/7125 Effectively Neutralizes SARS-CoV-2 Variants Including Omicron BA.1-BA.5, completed by the joint efforts of Boan...

Voluntary Announcement Grant of Exclusive Commercialization Rights of Boyoubei in Mainland China to CP Qingdao

Boan Biotech Partners with CP Qingdao to Accelerate the Commercialization of Boyoubei® in China

Yantai, January 10, 2023 —— Luye Pharma Group today announced that its subsidiary Boan Biotech has signed an agreement with CP Pharmaceutical Qingdao Co., Ltd. (CP Qingdao), to grant the latter the ...

Boan Biotech’s First Investigational ADC, BA1301 for Injection, Approved for Clinical Trials in China

January 09, 2023 - Luye Pharma Group announced today that BA1301 for injection, an innovative antibody-drug conjugate (ADC) candidate developed by its subsidiary Boan Biotech, has been approved for cl...